Logo image of ALAB

ASTERA LABS INC (ALAB) Stock Fundamental Analysis

NASDAQ:ALAB - Nasdaq - US04626A1034 - Common Stock - Currency: USD

95.9  -1.12 (-1.15%)

After market: 95.9 0 (0%)

Fundamental Rating

4

Overall ALAB gets a fundamental rating of 4 out of 10. We evaluated ALAB against 110 industry peers in the Semiconductors & Semiconductor Equipment industry. ALAB has a great financial health rating, but its profitability evaluates not so good. ALAB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ALAB was profitable.
ALAB had a positive operating cash flow in the past year.
ALAB Yearly Net Income VS EBIT VS OCF VS FCFALAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

ALAB has a Return On Assets (3.69%) which is in line with its industry peers.
ALAB has a Return On Equity (3.97%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA 3.69%
ROE 3.97%
ROIC N/A
ROA(3y)-16.28%
ROA(5y)N/A
ROE(3y)-19.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALAB Yearly ROA, ROE, ROICALAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -10 -20 -30

1.3 Margins

With a decent Profit Margin value of 8.44%, ALAB is doing good in the industry, outperforming 60.91% of the companies in the same industry.
ALAB has a better Gross Margin (75.76%) than 95.45% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 8.44%
GM 75.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALAB Yearly Profit, Operating, Gross MarginsALAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

ALAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALAB has more shares outstanding than it did 1 year ago.
ALAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALAB Yearly Shares OutstandingALAB Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 50M 100M 150M
ALAB Yearly Total Debt VS Total AssetsALAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 119.64 indicates that ALAB is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 119.64, ALAB belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
There is no outstanding debt for ALAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 119.64
ROIC/WACCN/A
WACC11.6%
ALAB Yearly LT Debt VS Equity VS FCFALAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 13.92 indicates that ALAB has no problem at all paying its short term obligations.
ALAB has a Current ratio of 13.92. This is amongst the best in the industry. ALAB outperforms 98.18% of its industry peers.
ALAB has a Quick Ratio of 13.26. This indicates that ALAB is financially healthy and has no problem in meeting its short term obligations.
ALAB has a Quick ratio of 13.26. This is amongst the best in the industry. ALAB outperforms 98.18% of its industry peers.
Industry RankSector Rank
Current Ratio 13.92
Quick Ratio 13.26
ALAB Yearly Current Assets VS Current LiabilitesALAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for ALAB have decreased strongly by -269.05% in the last year.
Looking at the last year, ALAB shows a very strong growth in Revenue. The Revenue has grown by 242.24%.
EPS 1Y (TTM)-269.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)242.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%144.33%

3.2 Future

ALAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.57% yearly.
ALAB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.10% yearly.
EPS Next Y37.64%
EPS Next 2Y32.63%
EPS Next 3Y34.57%
EPS Next 5YN/A
Revenue Next Year84.44%
Revenue Next 2Y54.21%
Revenue Next 3Y46.1%
Revenue Next 5YN/A

3.3 Evolution

ALAB Yearly Revenue VS EstimatesALAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
ALAB Yearly EPS VS EstimatesALAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 90.47, which means the current valuation is very expensive for ALAB.
The rest of the industry has a similar Price/Earnings ratio as ALAB.
ALAB is valuated expensively when we compare the Price/Earnings ratio to 27.41, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 54.52, the valuation of ALAB can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ALAB is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.19, ALAB is valued quite expensively.
Industry RankSector Rank
PE 90.47
Fwd PE 54.52
ALAB Price Earnings VS Forward Price EarningsALAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

ALAB's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 146.22
EV/EBITDA N/A
ALAB Per share dataALAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as ALAB's earnings are expected to grow with 34.57% in the coming years.
PEG (NY)2.4
PEG (5Y)N/A
EPS Next 2Y32.63%
EPS Next 3Y34.57%

More info and screens

0

5. Dividend

5.1 Amount

ALAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASTERA LABS INC

NASDAQ:ALAB (7/11/2025, 8:00:00 PM)

After market: 95.9 0 (0%)

95.9

-1.12 (-1.15%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners71.38%
Inst Owner Change0%
Ins Owners13.33%
Ins Owner Change-6.07%
Market Cap15.82B
Analysts83.64
Price Target101.7 (6.05%)
Short Float %7.7%
Short Ratio2.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27%
Min EPS beat(2)13.95%
Max EPS beat(2)40.06%
EPS beat(4)4
Avg EPS beat(4)25.56%
Min EPS beat(4)13.95%
Max EPS beat(4)40.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.08%
Min Revenue beat(2)2.08%
Max Revenue beat(2)8.09%
Revenue beat(4)4
Avg Revenue beat(4)6.98%
Min Revenue beat(4)2.08%
Max Revenue beat(4)13.78%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-18.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.6%
EPS NY rev (1m)0.64%
EPS NY rev (3m)7.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.74%
Valuation
Industry RankSector Rank
PE 90.47
Fwd PE 54.52
P/S 32.25
P/FCF 146.22
P/OCF 110.19
P/B 15.18
P/tB 15.18
EV/EBITDA N/A
EPS(TTM)1.06
EY1.11%
EPS(NY)1.76
Fwd EY1.83%
FCF(TTM)0.66
FCFY0.68%
OCF(TTM)0.87
OCFY0.91%
SpS2.97
BVpS6.32
TBVpS6.32
PEG (NY)2.4
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.69%
ROE 3.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 8.44%
GM 75.76%
FCFM 22.05%
ROA(3y)-16.28%
ROA(5y)N/A
ROE(3y)-19.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 964.8%
Cap/Sales 7.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 261.32%
Current Ratio 13.92
Quick Ratio 13.26
Altman-Z 119.64
F-Score7
WACC11.6%
ROIC/WACCN/A
Cap/Depr(3y)573.57%
Cap/Depr(5y)N/A
Cap/Sales(3y)5.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-269.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y37.64%
EPS Next 2Y32.63%
EPS Next 3Y34.57%
EPS Next 5YN/A
Revenue 1Y (TTM)242.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%144.33%
Revenue Next Year84.44%
Revenue Next 2Y54.21%
Revenue Next 3Y46.1%
Revenue Next 5YN/A
EBIT growth 1Y-293.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year146.28%
EBIT Next 3Y71.03%
EBIT Next 5YN/A
FCF growth 1Y761.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1174.83%
OCF growth 3YN/A
OCF growth 5YN/A